Home » Interviews » INTERVIEW: Why Sativa Investments Plc is to change its investment policy
Sativa Investments PLC

INTERVIEW: Why Sativa Investments Plc is to change its investment policy

Sativa Investments Plc (NEX:SATI) CEO Geremy Thomas talks to DirectorsTalk about the seeking of approval for a change in investment policy. Geremy provides us first with some background to the company, why the need for change, where the UK fits in the global market for medicinal cannabis and talks about other similar companies.

Sativa Investments Plc will looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with its initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.